who manufactures semaglutide FDA Warns on Certain Forms of Compounded Personalized GLP-1 - OurView

As the drug manufacturers Novo Nordisk and Eli Lilly have made exceedingly clear, these medicines are intended as long-term commitments, like medication for high blood pressure

On May 14, 2025, the judge overseeing the GLP-1 group lawsuit will hold a hearing about this matter where attorneys will get a chance to discuss this issue with experts

BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells

NICE guidance (NG28) recommends structured follow-up for patients on GLP-1 therapy, with specific continuation criteria that must be met to justify ongoing treatment